BioSpace

Tiziana touts multiple sclerosis win at lower dose as high dose misses mark

In a mid-stage trial, the lower dose of Tiziana’s intranasal monoclonal antibody reduced microglial activation in a specific type of multiple sclerosis. But the path forward remains unclear after the higher dose failed to deliver the same benefit.

By BioSpace

1 min read
Tiziana touts multiple sclerosis win at lower dose as high dose misses mark
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights